Last reviewed · How we verify
HPP2101
HPP2101 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders.
HPP2101 is a long-acting GLP-1 receptor agonist designed to improve glycemic control and promote weight loss in metabolic disorders. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | HPP2101 |
|---|---|
| Sponsor | Hanmi Pharmaceutical Company Limited |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
HPP2101 activates the glucagon-like peptide-1 (GLP-1) receptor, which enhances insulin secretion in response to glucose, slows gastric emptying, and promotes satiety. The extended half-life formulation allows for less frequent dosing compared to shorter-acting GLP-1 agonists, improving patient compliance while maintaining sustained metabolic benefits.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
Key clinical trials
- Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HPP2101 CI brief — competitive landscape report
- HPP2101 updates RSS · CI watch RSS
- Hanmi Pharmaceutical Company Limited portfolio CI